tbuckley/cabot-search huggingface dataset:
F<scp>ifty</scp> Y<scp>ears of</scp> R<scp>esearch in</scp> ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management
Authors: Takeshi Yoshida, Yuji Fujino, Marcelo B. P. Amato, Brian P. Kavanagh
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Spontaneous Breathing Cau...How Does a Spontaneous Br...Mechanisms of Injury from...Risk Factors for InjuryBenefits of Spontaneous E...Detection of Spontaneous ...Approach to ManagementConclusionsReferencesCITING ARTICLES
Correlation Between IL10 and CD8+ Cells in MDS Patients Adds New Insight Into the Role of the Immune System in This Disease
Authors: Matheus Rodrigues Lopes, Fabiola Traina, Joao Kleber Novais Pereira, Paula de Melo Campos, Joao Machado-Neto, Sara T. Olalla Saad, Patricia Favaro
Journal: Blood (2012)
Photothermally triggered on-demand insulin release from reduced graphene oxide modified hydrogels
Authors: Florina Teodorescu, Yavuz Oz, Gurvan Quéniat, Amar Abderrahmani, Catherine Foulon, Marie Lecoeur, Rana Sanyal, Amitav Sanyal, Rabah Boukherroub, Sabine Szunerits
Journal: Journal of Controlled Release (2016)
TCT-277 Frequency and risk factors of peri-stent contrast staining in chronic total occluded lesion
Authors: None katsuya miura, Kazushige Kadota, Hiroyuki Tanaka, Takeshi Tada, Akimune Kuwayama, Masanobu Ohya, Takenobu Shimada, Hidewo Amano, Shunsuke Kubo, Yusuke Hyodo, Suguru Otsuru, Seiji Habara, Yasushi Fuku, Tsuyoshi Goto
Journal: Journal of the American College of Cardiology (2016)
RESECCIÓN ENDOSCÓPICA RADICAL DE ADENOCARCINOMA DE SIGMA CON INFILTRACIÓN DE LA SUBMUCOSA
Authors: C De Zárraga Mata, G Thomas Salom, LN Amado Villanueva, ÁL Maura Oliver, AI De Hita Santabaya, C Dolz Abadía
Journal: Endoscopy (2016)

Presentamos el caso de un varón de 42 años de edad, consumidor de 15 cigarrillos y 25 g de alcohol diarios con hepatitis crónica por VHC. Realiza tratamiento del VHC con simeprevir y sofosbuvir, negativizándose la carga viral. En este contexto se le detecta ferropenia (no atribuible al tratamiento recibido). El test de sangre oculta en heces es positivo así que se programa una colonoscopia.
Use of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolic Events in Acutely Ill Medical Patients: A Meta-Analysis of Individual Patient Data.
Authors: Patrick Mismetti, Jérôme Liotier, Franz-Xaver Kleber, David G. Sherman, Nathalie Moulin, Silvy Laporte
Journal: Blood (2007)
Neuronal firing patterns outweigh circuitry oscillations in parkinsonian motor control
Authors: Ming-Kai Pan, Sheng-Han Kuo, Chun-Hwei Tai, Jyun-You Liou, Ju-Chun Pei, Chia-Yuan Chang, Yi-Mei Wang, Wen-Chuan Liu, Tien-Rei Wang, Wen-Sung Lai, Chung-Chin Kuo
Journal: Journal of Clinical Investigation (2016)

Neuronal oscillations at beta frequencies (20-50 Hz) in the cortico-basal ganglia circuits have long been the leading theory for bradykinesia, the slow movements that are cardinal symptoms in Parkinson's disease (PD). The beta oscillation theory helped to drive a frequency-based design in the development of deep brain stimulation therapy for PD. However, in contrast to this theory, here we have found that bradykinesia can be completely dissociated from beta oscillations in rodent models. Instead, we observed that bradykinesia is causatively regulated by the burst-firing pattern of the subthalamic nucleus (STN) in a feed-forward, or efferent-only, mechanism. Furthermore, STN burst-firing and beta oscillations are two independent mechanisms that are regulated by different NMDA receptors in STN. Our results shift the understanding of bradykinesia pathophysiology from an interactive oscillatory theory toward a feed-forward mechanism that is coded by firing patterns. This distinct mechanism may improve understanding of the fundamental concepts of motor control and enable more selective targeting of bradykinesia-specific mechanisms to improve PD therapy.
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy
Authors: F. Perrone, C. Jommi, M. Di Maio, A. Gimigliano, C. Gridelli, S. Pignata, F. Ciardiello, F. Nuzzo, A. de Matteis, L. Del Mastro, J. Bryce, G. Daniele, A. Morabito, M.C. Piccirillo, G. Rocco, L. Guizzaro, C. Gallo
Journal: Annals of Oncology (2016)
Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation
Authors: Gabriel N. Mannis, Thomas G. Martin, Lloyd E. Damon, Charalambos Andreadis, Rebecca L. Olin, Katie Kong, Malek Faham, Weiyun Z. Ai, Karin ML Gaensler, Peter H. Sayre, Jeffrey L. Wolf, Aaron C. Logan
Journal: Blood (2015)
BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study
Authors: Heather Greenlee, Dawn L. Hershman, Zaixing Shi, Marilyn L. Kwan, Isaac J. Ergas, Janise M. Roh, Lawrence H. Kushi
Journal: JNCI Journal of the National Cancer Institute (2016)

Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer.Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m2; overweight: 25-29.9 kg/m2; obese: ≥30 kg/m2), moderate-to-vigorous physical activity (MVPA) (low: <2.5; medium: 2.5-5; high: >5 hours/week) and fruit/vegetable intake (low: <35 servings/week; high: ≥35 servings/week). Baseline and six-month interviews assessed antioxidant supplement use (nonuser, discontinued, continued user, initiator). CIPN was assessed at baseline, six months, and 24 months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX); a 10% decrease was considered clinically meaningful.At baseline, 65.6% of patients in the sample were overweight or obese, 29.9% had low MVPA, 57.5% had low fruit/vegetable intake, and 9.5% reported antioxidant supplement use during treatment. In multivariable analyses, increased CIPN was more likely to occur in overweight (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.19 to 4.88) and obese patients (OR = 3.21, 95% CI = 1.52 to 7.02) compared with normal weight patients at 24 months and less likely to occur in patients with high MVPA compared with those with low MVPA at six (OR = 0.56, 95% CI = 0.34 to 0.94) and 24 months (OR = 0.43, 95% CI = 0.21 to 0.87). Compared with nonusers, patients who initiated antioxidant use during treatment were more likely to report increased CIPN at six months (OR = 3.81, 95% CI = 1.82 to 8.04).Obesity and low MVPA were associated with CIPN in breast cancer patients who received taxane treatment.
TCT-381 Effects Of Acute Kidney Injury and Chronic Kidney Disease on Mortality In Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Rafael Alexandre Meneguz-Moreno, Auristela Ramos, Antonio Castro-Filho, Tannas Jatene, Andreia Jeronimo, David Le Bihan, Rodrigo Barretto, Dimytri Siqueira, Magaly Arrais, Adriana Moreira, Alexandre Abizaid, Amanda Sousa, J. Eduardo Sousa
Journal: Journal of the American College of Cardiology (2016)
Population pharmacokinetic analysis of S-1 including the <i>CYP2A6</i> genotype in patients with advanced cancer
Authors: T. Hirose, K. Nishimura, K. Fujita, M. Adachi, Y. Sasaki, Y. Tanigawara
Journal: Journal of Clinical Oncology (2009)

2507 Background: S-1 is an oral anticancer agent composed of tegafur, CDHP, and potassium oxonate. Tegafur is a prodrug of fluorouracil (5-FU), and CDHP prevents degradation of 5-FU by inhibiting dihydropyrimidine dehydrogenase and enhances the anticancer activity of 5-FU. The biotransformation of tegafur to 5-FU is demonstrated to be catalyzed by CYP2A6. CYP2A6 polymorphisms are seen more frequently in Japanese people than Caucasian. Therefore, we performed a population pharmacokinetic (PPK) analysis of S-1 including the CYP2A6 genotype in Japanese patients with advanced cancer and developed a model describing the disposition kinetics of tegafur, CDHP, and 5-FU after oral administration of S-1. Methods: Fifty-eight patients with advanced cancer were eligible if they had a performance status of 0 to 3 and had adequate organ function. A dose of 80 mg/m 2 of S-1 was given orally twice daily for 28 consecutive days, followed by 14 days of rest. The PPK analysis was performed with plasma concentration data for tegafur, CDHP, and 5-FU. The CYP2A6 genotype was analyzed with the polymerase chain reaction-restriction fragment length polymorphism method or an allele-specific polymerase chain reaction-based method. On the basis of the CYP2A6 genotype, all patients were classified into 1 of 3 groups: wild type, 1 variant allele, and 2 variant alleles. Results: Creatinine clearance correlated with the individual clearance of CDHP. Body surface area correlated with the individual clearance and volumes of CDHP and tegafur. In patients with 2 variant alleles of CYP2A6, tegafur clearance was 58% less than that in patients with wild type or 1 variant allele of CYP2A6. In addition, in patients with a history of gastrectomy, the absorption rate constant of tegafur was 66% higher than that in patients with no history of gastrectomy. The time-varying concentration of CDHP was the most appropriate model component describing the inhibitory effect on 5-FU catabolism. The individual Bayesian predictions of CDHP, tegafur, and 5-FU concentrations based on the present PPK model were in good agreement with the observed data. Conclusions: This is the first PPK model of S-1 including the CYP2A6 genotype. No significant financial relationships to disclose.
TCT-520 Qualitative Resting Wave Form Analysis to Predict an Abnormal Fractional Flow Reserve (FFR): A CONTRAST FFR Sub-Study
Authors: Mitsuaki Matsumura, Akiko Maehara, Nils Johnson, William Fearon, Bernard De Bruyne, Keith Oldroyd, Nico Pijls, Paul Jenkins, Gary Mintz, Gregg Stone, Allen Jeremias
Journal: Journal of the American College of Cardiology (2016)
Deconstructing Pretest Risk Enrichment to Optimize Prediction of Psychosis in Individuals at Clinical High Risk
Authors: Paolo Fusar-Poli, Grazia Rutigliano, Daniel Stahl, André Schmidt, Valentina Ramella-Cravaro, Shetty Hitesh, Philip McGuire
Journal: JAMA Psychiatry (2016)

Pretest risk estimation is routinely used in clinical medicine to inform further diagnostic testing in individuals with suspected diseases. To our knowledge, the overall characteristics and specific determinants of pretest risk of psychosis onset in individuals undergoing clinical high risk (CHR) assessment are unknown.To investigate the characteristics and determinants of pretest risk of psychosis onset in individuals undergoing CHR assessment and to develop and externally validate a pretest risk stratification model.Clinical register-based cohort study. Individuals were drawn from electronic, real-world, real-time clinical records relating to routine mental health care of CHR services in South London and the Maudsley National Health Service Trust in London, United Kingdom. The study included nonpsychotic individuals referred on suspicion of psychosis risk and assessed by the Outreach and Support in South London CHR service from 2002 to 2015. Model development and validation was performed with machine-learning methods based on Least Absolute Shrinkage and Selection Operator for Cox proportional hazards model.Pretest risk of psychosis onset in individuals undergoing CHR assessment. Predictors included age, sex, age × sex interaction, race/ethnicity, socioeconomic status, marital status, referral source, and referral year.A total of 710 nonpsychotic individuals undergoing CHR assessment were included. The mean age was 23 years. Three hundred ninety-nine individuals were men (56%), their race/ethnicity was heterogenous, and they were referred from a variety of sources. The cumulative 6-year pretest risk of psychosis was 14.55% (95% CI, 11.71% to 17.99%), confirming substantial pretest risk enrichment during the recruitment of individuals undergoing CHR assessment. Race/ethnicity and source of referral were associated with pretest risk enrichment. The predictive model based on these factors was externally validated, showing moderately good discrimination and sufficient calibration. It was used to stratify individuals undergoing CHR assessment into 4 classes of pretest risk (6-year): low, 3.39% (95% CI, 0.96% to 11.56%); moderately low, 11.58% (95% CI, 8.10% to 16.40%); moderately high, 23.69% (95% CI, 16.58% to 33.20%); and high, 53.65% (95% CI, 36.78% to 72.46%).Significant risk enrichment occurs before individuals are assessed for a suspected CHR state. Race/ethnicity and source of referral are associated with pretest risk enrichment in individuals undergoing CHR assessment. A stratification model can identify individuals at differential pretest risk of psychosis. Identification of these subgroups may inform outreach campaigns and subsequent testing and eventually optimize psychosis prediction.
First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
Authors: Jian-Ming Xu, Yan Wang, Yu-ling Chen, Ru Jia, Lin Shen, Jian Wang, Yang Sai, Chuan Qi, Hua MU
Journal: Journal of Clinical Oncology (2014)

2615 Background: Sulfatinib is a highly selective oral small molecule tyrosine dual inhibitor of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). The FIH phase I data of the original formulation was reported in ASCO 2013(abs#3040). A milled formulation was subsequently developed to improve the PK property of this compound. Methods: This phase I dose-escalation study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetic (PK) profiles, and preliminary antitumor activity of sulfantinib when given orally in continuous cycles of 28 days, until disease progression or unacceptable toxicity. Results: Totally 60 pts have been enrolled (43 were treated with original formulation and 17 with milled formulation). For the 17 pts treated with milled sulfatinib at doses of 200mg, 300mg and 350mg once daily, the median age was 57 (23-69) yrs, with 82% male. Common adverse events included hypertension, nausea, diarrhea and elevated AST/ALT, mostly grade1/2. No DLT was observed. MTD has not been reached. PK analyses showed that drug exposures in terms of Cmax and AUC was increased while the inter- and intra-individual variability was reduced with milled formulation comparing to original formulation, indicating improved oral absorption. A reasonable 2-fold accumulation was observed at steady-state with t1/2 of 20.2±4.75 h and 15.4±3.66 h at 200 and 300 mg, respectively. Among 13 evaluable pts, partial response (PR) was observed in 4 pts (ORR 30%) including 1 HCC in 200mg QD cohort, 1 liver neuroendocrine tumor (NET) and 1 NET with unknown primary site in 300mg cohort, and 1 lymph node NET in 350mg cohort. 7 (54%) pts had stable disease. Conclusions: Sulfatinib in milled formulation was well tolerated at doses up to 350 mg daily and demonstrated improved oral absorption and reduced exposure variability. Encouraging preliminary clinical efficacy including PR in pts with HCC and NET was observed. Further clinical development with sulfatinib milled formulation is warranted. Clinical trial information: CTR20131070.
Fetal Hemoglobin In Sickle Cell Anemia: Molecular Characterization of the High Fetal Hemoglobin Phenotype In African American Patients
Authors: Idowu Akinsheye, Nadia Solovieff, Anita Malek, Duyen A. Ngo, Martin H. Steinberg, David H.K. Chui
Journal: Blood (2010)
P0572 : The impact of hepatitis B virus (HBV) infection on prognosis of patients with diffuse large B-cell lymphoma and the occurrence of hepatitis flares after withdrawal of prophylactic antiviral treatment on completion of chemotherapy
Authors: M.F. Law, H.N. Chan, H.K. Lai, C.Y. Ha, C. Ng, Y.M. Yeung, S.F. Yip
Journal: Journal of Hepatology (2015)
Invasive Fusariosis in Patients with Hematologic Malignancies at a University Hospital
Authors: Vildan Ozkocaman, Fahir Ozkalemkas, Burcu Dalyan Cilo, Tugcan Alp, Tuba Ersal, Erdem Gozden, Zafer Serenli Yegen, Ali Ridvan, Beyza Ener
Journal: Blood (2015)
Association Between Stillbirth and Risk Factors Known at Pregnancy Confirmation
Journal: JAMA (2011)

Context-Stillbirths account for almost half of US deaths from 20 weeks' gestation to 1 year of life.Most large studies of risk factors for stillbirth use vital statistics with limited data.Objective-To determine the relation between stillbirths and risk factors that could be ascertained at the start of pregnancy, particularly the contribution of these factors to racial disparities.Design, Setting, and Participants-Multisite population-based case-control study conducted between March 2006 and September 2008.Fifty-nine US tertiary care and community hospitals, with access to at least 90% of deliveries within 5 catchment areas defined by state and county lines, enrolled residents with deliveries of 1 or more stillborn fetuses and a representative sample of deliveries of only live-born infants, over-sampled for those at less than 32 weeks' gestation and those of African descent. Main Outcome Measure-Stillbirth.Results-Analysis included 614 case and 1816 control deliveries.In multivariate analyses, the following factors were independently associated with stillbirth: non-Hispanic black race/ethnicity (23.1% stillbirths, 11.2% live births) (vs non-Hispanic whites; adjusted odds ratio [AOR], 2.12 [95% CI, 1.41-3.20]);previous stillbirth (6.7% stillbirths, 1.4% live births); nulliparity with (10.5% stillbirths, 5.2% live births) and without (34.0%stillbirths, 29.7% live births) previous losses at fewer than 20 weeks' gestation (vs multiparity without stillbirth or previous losses; AOR, 5.91 [95% CI, 3.18-11.00];AOR, 3.13 [95% CI, 2.06-4.75];and AOR, 1.98 [95% CI, 1.51-2.60],respectively); diabetes (5.6% stillbirths, 1.6% live births) (vs no diabetes; AOR, 2.50 [95% CI, 1.39-4.48]);maternal age 40 years or older (4.5% stillbirths, 2.1% live births) (vs age 20-34 years; AOR, 2.41 [95% CI, 1.24-4.70]);maternal AB blood type (4.9% stillbirths, 3.0% live births) (vs type O; AOR, 1.96 [95% CI, 1.16-3.30]);history of drug addiction (4.5% stillbirths, 2.1% live births) (vs never use; AOR, 2.08 [95% CI, 1.12-3.88]);smoking during the 3 months prior to pregnancy (<10 cigarettes/d, 10.0% stillbirths, 6.5% live births) (vs none; AOR, 1.55 [95% CI, 1.02-2.35]);obesity/overweight (15.5% stillbirths, 12.4% live births) (vs normal weight; AOR, 1.72 [95% CI, 1.22-2.43]);not living with a partner (25.4% stillbirths, 15.3% live births) (vs married; AOR, 1.62 [95% CI, 1.15-2.27]);and plurality (6.4% stillbirths, 1.9% live births) (vs
TCT-577 Intravascular ultrasound guidance during percutaneous coronary intervention using second-generation drug-eluting stents improves clinical outcomes and reduces restenosis rates: a comparative 8,265 patient meta-analysis
Authors: Kunal Verma, Caitlin Cheshire, Nitesh Nerlekar, Liam McCormick, James Cameron, Martin Bennett, Ian Meredith, Adam Brown
Journal: Journal of the American College of Cardiology (2016)
Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab
Authors: Gregory A. Rufener, Philip Olsen, Sang Yun Lee, Michael C Jensen, Ajay K. Gopal, Barbara Pender, Damian J. Green, David G. Maloney, Stanley R. Riddell, Oliver W Press, Brian G. Till
Journal: Blood (2015)
Mesenchymal Stem Cells Relieve Chronic GVHD Via Modulation the Ratio of CD8+CD28-/CD8+CD28+T Cells.
Authors: Jianyu Weng, Xin Du, Suxia Geng, Maohua Zhou, Yanwen Peng, Zhen Wang, Zesheng Lu, Suijing Wu, Chenwei Luo, Rong Guo, Wei Ling, Chengxin Deng, Pengjun Liao, Andy Peng Xiang
Journal: Blood (2009)
ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis
Authors: James Yao, Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot Tesselaar, Edward Wolin, Eric Van Cutsem, Paola Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Pacaud, Antonia Ridolfi, Simron Singh, Marianne Pavel, Matthew Kulke
Journal: Journal of Thoracic Oncology (2016)
Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial.
Authors: J. S. Temel, J. Greer, E. Gallagher, S. Admane, W. F. Pirl, V. Jackson, C. Dahlin, A. Muzikansky, J. Jacobsen, T. J. Lynch
Journal: Journal of Clinical Oncology (2010)

7509 Background: Patients withmetastatic NSCLC face significant physical and psychological symptoms and receive aggressive care at the EOL. The goal of this study was to examine the impact of early PC on patient-reported and EOL care outcomes in newly diagnosed patients. Methods: Randomized study of early PC with oncology care versus standard oncology care (SC) in patients with newly diagnosed metastatic NSCLC. Eligible patients had a PS of 0-2 and were within 8 weeks of diagnosis of metastatic disease. Prior to randomization, patients completed baseline measures of QOL (FACT-Lung) and mood (HADS and PHQ-9). Patients were randomized 1:1 to early PC (at least monthly PC visits from the time of enrollment) or SC. QOL and mood assessments were performed at 12 weeks and patients were followed until death. Data on care received at the EOL (hospice utilization, length of stay on hospice ≤ 3 days, chemotherapy in the last 14 days of life, and survival) were also collected. The primary outcome was the change in the FACT-Lung Trial Outcome Index (TOI) at 12 weeks and the study had 80% power to detect an effect size of 0.55 of the standard deviation between arms. Results: Between June 2006 and July 2009, 151 patients were randomized. There were no significant baseline differences between groups. At 12 weeks, 27 patients had died (17 PC and 10 SC), and 107 (86%) patients completed assessments. Patients assigned to early PC experienced better QOL, as measured by the FACT-Lung (98.0 v 91.5, p = 0.03) and TOI (59.0 v 53.0, p = 0.01) and had lower rates of depression, as measured by both the HADS (15.8 v 38.3%, p = 0.01) and the PHQ-9 (3.5 v 17%, p = 0.02) compared to SC. Fewer patients randomized to early PC received aggressive care at the EOL compared with SC patients (33.3 v 53.6%, p = 0.05). Despite receiving less aggressive care at the EOL, patients receiving early PC had longer survival compared with SC (11.6 m v 8.0 m, p = 0.02). Conclusions: Early PC in patients with newly diagnosed metastatic NSCLC led to significant improvements in both mood and QOL. Patients receiving early PC experienced less aggressive care at the EOL, yet prolonged survival, compared with SC patients. No significant financial relationships to disclose.
FACTORES PREDICTIVOS DE LA EFICACIA DIAGNÓSTICA DE LA PUNCIÓN GUIADA POR ECOENDOSCOPIA DE MASAS PANCREÁTICAS SÓLIDAS
Authors: N Quintáis Pinazas, D Martínez-Ares, A Rincón Gatica, B Romero Mosquera, MJ Álvarez Martín, B San Millán Tejado, R Fernández Martín, N Alfonsin Barreiro, JI Rodríguez Prada
Journal: Endoscopy (2016)

El diagnóstico histológico de las masas pancreáticas es una de las principales indicaciones de la PAAF guiada por ecoendoscopia. Ello sigue suponiendo un reto para el ecoendoscopista, por lo que es de gran importancia la adopción que permitan optimizar el proceso diagnóstico.
TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa Aquino, Thomas Stuckey, Timothy Henry, David Moliterno, David Cohen, Philippe Gabriel Steg, Ioannis Iakovou, Jeffrey Bruckel, Stuart Pocock, Annapoorna Kini, Antonio Colombo, Alaide Chieffo, Bernhard Witzenbichler, Giora Weisz, George Dangas, C. Michael Gibson, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)